Global Biologics Market Size is valued at USD 426.1 Bn in 2024 and is predicted to reach USD 890.2 Bn by the year 2034 at a 7.8% CAGR during the forecast period for 2025-2034.
Biologics are drugs manufactured from organic materials that can treat various disorders, including immune-related illnesses such as Crohn's disease, psoriasis, ankylosing spondylitis, and rheumatoid arthritis. The intriguing feature is that biologics are isolated from various natural sources, whether carbohydrates, proteins, nucleic acids, or a complex mixture of these materials.
The improved understanding of disease's genetic and molecular foundation has paved the way for creating various tailored treatments. Recmbinant proteins, for example, help the immune system identify and bind foreign molecules. Advances in manufacturing capability development are expected to increase biopharmaceutical production capacity. The use of single-use systems in the synthesis and processing of biopharmaceuticals is also among these breakthroughs.
However, the COVID-19 pandemic had a large market impact. During the pandemic, there was a huge demand for biologics, which contributed significantly to the market's rise. For example, the National Research Council of Canada and China-based CanSino Biologics collaborated on the development of a COVID-19 vaccine in Canada in May 2020. During the pandemic, the considerable research and development operations for the treatment of COVID-19 contributed considerably to the expansion of the biologics market.
The biologics market is segmented based on source, product, disease, manufacturing, route of administration, drug classification, mode of purchase, distribution channel. Based on source, the market is segmented as microbial, mammalian, and others. The products segment includes MABs, Vaccines, Antisense, RNAi & Molecular Therapy, Recombinant Proteins, Others. By disease category, the market is segmented into Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Others. Manufacturing segment includes Outsourced, In-house, Route of Administration segment includes Oral and Others (IV and IP), Drug Classification segment includes Branded & Generic Drugs, Mode of Purchase segment includes Prescription & Over-The-Counter (OTC) Drugs, and Distribution Channel segment includes Hospital, Retail and online.
The microbial category is expected to hold a major share of the global Biologics Market in 2022. This is attributed to the high number of medications developed by employing these products. Microbial expression systems commonly include E. Coli and yeast. Recombinant insulin, granulocyte-macrophage colony-stimulating factor, platelet-derived growth factor, and recombinant interferon are all products of these expression systems. Companies utilizing microbial systems include Johnson & Johnson, Novartis, and Genentech.
The oncology segment is projected to grow at a rapid rate in the global Biologics Market owing to the rising incidence of cancer coupled with the presence of different R&D programs. These efforts include cancer-eradication gene treatments and antisense therapeutics. Additionally, oncology is expected to retain its supremacy during the predicted period. The increased use of goods to lessen the number of adverse effects connected with the use of cancer chemotherapy is one of the drivers for the expected growth.
The North America Biologics Market is expected to register the highest market share in terms of revenue in the near future. This can be attributed to significant corporations, engaging reimbursement policies, and considerable R&D investment. In the United States, biologics account for around 38% of overall medication spending. Approval of new biologic drugs will likely boost market expansion throughout the projection period; for example, the US FDA approved 21 BLAs in 2021. Because of increased R&D spending for biologic development, as well as the availability of a high number of FDA-approved biologics in the country, the United States market for biologics will account for a considerable proportion in 2021. In addition, Germany holds the largest proportion of the European biologics market.
The presence of a sophisticated manufacturing sector, favorable reimbursement, the availability of several approved medications, and the target patient group all contribute to this market's supremacy in Europe.
|
Report Attribute |
Specifications |
|
Market size value in 2024 |
USD 426.1 Bn |
|
Revenue Forecast in 2034 |
USD 890.2 Bn |
|
Growth rate CAGR |
CAGR of 7.8% from 2025 to 2034 |
|
Quantitative units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
|
Segments covered |
Source, Product, Disease, Manufacturing, Route of Administration, Drug Classification, Mode of Purchase, Distribution Channel |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Samsung BioLogics; Amgen; Novo Nordisk A/S; AbbVie Inc.; Sanofi; Pfizer Inc.; Inc.; GSK group of companies; Merck & Co., Celltrion; Precision Biologics, Inc.; Johnson & Johnson Services, Inc; Eli Lilly and Company; Novartis AG; Merck KGaA; Bayer AG; F. Hoffmann-La Roche Ltd; and AstraZeneca |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Biologics Market By Source
Biologics Market By Product
Biologics Market By Disease
Biologics Market By Manufacturing
Biologics Market By Route of Administration
Biologics Market By Drug Classification
Biologics Market By Mode of Purchase
Biologics Market By Distribution Channel
Biologics Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
